Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), BioCryst (BCRX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and BioCryst (BCRX – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Abbott Laboratories (ABT)
In a report issued on January 20, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Abbott Laboratories, with a price target of $147.00. The company’s shares closed last Wednesday at $120.73.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Laboratories with a $150.07 average price target, representing a 23.3% upside. In a report issued on January 5, Evercore ISI also maintained a Buy rating on the stock with a $144.00 price target.
See today’s best-performing stocks on TipRanks >>
BioCryst (BCRX)
RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst on January 20 and set a price target of $14.00. The company’s shares closed last Wednesday at $6.72.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $19.80, implying a 197.3% upside from current levels. In a report issued on January 15, TipRanks – Google also upgraded the stock to Buy with a $7.50 price target.
